Drugmakers remain attractive employers in Belgium

23 February 2009

Belgium's research-based pharmaceutical industry association, pharma.be, has welcomed the findings of a study of employers which shows that  drugmakers remain one of the most desirable sectors in which to work.  The Randstad Award 2009 survey gathers ratings from members of the  public according to 10 criteria, including salary level, future  prospects and training. In all but one of these ("respect for the  environment and society"), the drug sector was in the top two places.

In addition, four pharmaceutical firms finished in the top 10 companies  in Belgium to work for, all of them the local subsidiaries of foreign  R&D-based companies: second-placed GlaxoSmithKline; fourth-placed  Janssen Pharmaceutica; fifth-placed Pfizer; and ninth-ranked Bayer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >




Today's issue

Company Spotlight